Joining forces: when to escalate therapy

N. Galie (Bologna, Italy)

Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience
Disease area: Pulmonary vascular diseases

Multimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Galie (Bologna, Italy). Joining forces: when to escalate therapy. Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
WHO and Tobacco Control. Joining efforts with ERS
Source: International Congress 2017 – Hot topic on tobacco prevention and cessation
Year: 2017


Spacer devices for inhaled therapy: why use them, and how?
Source: ERJ Open Res, 4 (2) 00065-2018; 10.1183/23120541.00065-2018
Year: 2018



Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Year: 2020




Late Breaking Abstract - Identifying and addressing patient beliefs driving SABA use and over-reliance
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019



Combating acquired resistance: are rebiopsies needed for guiding multi-line therapies?
Source: International Congress 2015 – Non-small cell lung cancer (NSCLC): sequence, timing, and modality of multi-line therapies
Year: 2015



Tuberculosis elimination, patients' lives and rational use of new drugs: revisited
Source: Eur Respir J 2016; 47: 664-667
Year: 2016


Optimising drug distribution throughout the bronchial tree: new perspectives
Source: Annual Congress 2008 - Improving pulmonary distribution of combination therapy: implications for asthma treatment
Year: 2008

Late Breaking Abstract - Therapeutic drug monitoring in a patient with very advanced XDR-TB
Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis
Year: 2021


We must join forces in the battle against COPD
Source: Eur Respir J 2015; 46: 1528
Year: 2015


We must join forces in the battle against COPD
Source: Eur Respir J 2015; 46: 1526-1528
Year: 2015


Late Breaking Abstract - Severe pneumonia patients may could not benefit from antibiotic combination therapy and non-invasive ventilation(NIV), despite the advanced mode
Source: International Congress 2018 – Non-invasive ventilation for acute respiratory failure
Year: 2018


Ward-based oxygen therapy audit: Prescribe, target, deliver
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016


Ineffective efforts. Contribution of non-linear dynamics?
Source: Annual Congress 2008 - Patient-ventilator interactions during ventilation
Year: 2008


Antibiotic choice, route and duration: minimising the harm associated with antibiotics
Source: Eur Respir Monogr 2014; 63: 155-167
Year: 2014


Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016


Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021